Impact of body size on platelet function in patients with acute coronary syndrome on dual antiplatelet therapy.
Body indices
Dual antiplatelet therapy
P2Y(12) receptor
PAR-1 receptor
Prasugrel
Ticagrelor
Journal
Vascular pharmacology
ISSN: 1879-3649
Titre abrégé: Vascul Pharmacol
Pays: United States
ID NLM: 101130615
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
17
05
2022
revised:
14
07
2022
accepted:
16
07
2022
pubmed:
24
7
2022
medline:
14
10
2022
entrez:
23
7
2022
Statut:
ppublish
Résumé
Patients undergoing acute percutaneous coronary intervention receive dual antiplatelet therapy for secondary prevention. Recurrent myocardial infarction or bleedings are possibly due to under- or overdosing of antiplatelet therapy in relation to body size. We correlated residual platelet aggregation with body mass index, body surface area, lean body mass and blood volume in 220 patients on prasugrel (n = 121) or ticagrelor (n = 99). Platelet aggregation outside the recommended window was recorded in 85 patients, but not correlated with any of the body indices. Body size does not affect platelet response to prasugrel or ticagrelor at the guideline-recommended fixed dosages.
Identifiants
pubmed: 35870771
pii: S1537-1891(22)00138-0
doi: 10.1016/j.vph.2022.107089
pii:
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Purinergic P2Y Receptor Antagonists
0
Prasugrel Hydrochloride
G89JQ59I13
Ticagrelor
GLH0314RVC
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
107089Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors of this manuscript have nothing to declare.